Phaseline

Companies › TScan Therapeutics

TScan Therapeutics: clinical trials, targets and expected readouts

5 active drug programs in 7 registered trials: 6 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TSC-101
T-cell receptor engineered donor T cells targeting HA-2
HA2Phase 3AMLJun 2028
TSC-200-A0201
Autologous TCR-T cell therapy targeting cancer-associated antigens presented on HLA molecu
–Phase 1Head and Neck CancerDec 2026
TSC-204-A0201
Autologous TCR-T cell therapy targeting cancer-associated antigens presented on HLA molecu
–Phase 1Head and Neck CancerDec 2026
TSC-204-C0702
Autologous TCR-T cell therapy targeting cancer-associated antigens presented on HLA molecu
–Phase 1Head and Neck CancerDec 2026
TSC-100
T-cell receptor engineered donor T cells targeting HA-1 antigen
–Phase 1AMLJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05973487TSC-204-A0201Phase 1Head and Neck CancerOncologyDec 2026
NCT05973487TSC-204-A0201Phase 1Head and Neck CancerOncologyDec 2026
NCT05973487TSC-204-C0702Phase 1Head and Neck CancerOncologyDec 2026
NCT05973487TSC-200-A0201Phase 1Head and Neck CancerOncologyDec 2026
NCT05473910TSC-101Phase 1AMLOncologyJun 2028
NCT05473910TSC-100Phase 1AMLOncologyJun 2028
NCT07702578TSC-101Phase 3AMLOncologyJun 2029

From the company's SEC filings

Cash of $100m on 2026-06-30; operating cash outflow about $105m a year; runway about 11 months at that burn, to Jun 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

HA2 (1)

Companies with the same targets

–

Companies built like this

MacroGenics Tyra Biosciences Binhui Biopharmaceutical UroGen Pharma Radiopharm Theranostics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.